The addition of sorafenib to intensive chemotherapy had a significant impact on the survival rate of patients with FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
In this study, we investigated the effect of EDO-S101 in combination with cytarabine in treating AML cells. The synergic activity against AML was identified by remarkable reduction of cell viability, significant apoptosis enhancement and the upregulation of the cleaved PARP, Casepase-3 and -7 proteins compared with monotherapy. To explain the drivers, we detected the DNA damage pathway including DNA double-strand breaks marker γ-H2AX and DNA damage checkpoint proteins, which was supposed to be responsible for the enhanced apoptosis activity. In summary, our data demonstrated that EDO-S101 in combination with cytarabi…
Conclusion: The results indicate that oral candidiasis is a prevalent fungal infection in the patients with hematologic malignancies with C. albicans being the main etiological agent. However, other species of Candida cause similar infections in these patients.
PMID: 31341565 [PubMed]
Authors: Khodashahi R, Hakemi-Vala M, Mardani M, Abolghasemi S, Lotfali E, Arab-Mazar Z, Omidi N, Ghasemshahi S
Background and Objectives: The aim of this study was to determine the drug susceptibility pattern of the pathogens causing bacteraemia and fungemia in patients who have developed febrile neutropenia after chemotherapy.
Materials and Methods: A total of 95 patients with suspected or proven malignancy (50 patients) were admitted to the adult haematology ward at Taleghani Hospital in Tehran. Blood samples were inoculated into the bottles of Bact/Alert blood culture system and sent to Payvand’s c…
Systemic mastocytosis (SM) is a disorder characterized by abnormal proliferation of mast cells with KIT mutations, especially in codon 816. The prognosis of patients developing acute myeloid leukemia (AML) from SM is extremely poor, and hematopoietic cell transplantation is recommended. Herein, we describe a case of an 8-year-old female diagnosed with SM developing AML. A KIT M541L variant in SM was identified in leukemic cells, normal hematopoietic cells, and buccal mucosal cells, suggesting a germline polymorphism. The patient has remained in complete remission for 39 months after completion of chemotherapy. SM developin…
With the exception of bladder cancer, the frequency of KDM6A gene mutations in malignancy is thought to be rather low in malignant developments. A new study published in Leukemia is suggesting that the loss of KDM6A in patients with acute myeloid leukemia (AML) may provide cells with a selective advantage during chemotherapy, leading to the development of clones with KDM6A mutations or reduced KDM6A expression at the time of relapse. A majority of patients with AML relapse due to intrinsic or acquired drug resistance.
Conclusions: Decitabine-based chemotherapy may be a suitable therapeutic alternative for newly diagnosed AML patients who are unfit for intensive chemotherapy. An advanced age (≥ 60 years) and higher MRD (≥ 1.34%) were considered adverse prognostic factors.
PMID: 31315553 [PubMed – in process]
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 Interventions: Drug: Gilteritinib; Drug: Midostaurin Sponsors: Stichting Hemato-Oncologie voor Volwassenen Nederland; Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG); Astellas Pharma Global Development, Inc. Not yet recruiting
AbstractThe hypocellular acute leukemia is very rare atypical leukemia with frequency of 5 –7% among patients with acute leukemias. It mainly occurs in older patients and usually has a myeloid phenotype. It is still unclear whether the outcome of hypocellular acute myeloid leukemia is less favorable than adult acute myeloid leukemia with normal cellularity. We retrospectively analyzed a ll hypocellular acute myeloid leukemias which were treated in 16 years period, between January 1998 and December 2014. There were 33 patients, 21 male and 12 female. The median age of the patients was 58.9 years (ranging fro…
Decitabine combined with chemotherapy is therefore offered as a new induction choice for newly diagnosed acute myeloid leukemia patients aged